Mirabegron reduces urinary frequency and improves overactive bladder symptoms at 3 months after 125I-brachytherapy for prostate cancer: An open-labeled, randomized, non-placebo-controlled study.
Sign Up to like & getrecommendations! Published in 2021 at "Urology"
DOI: 10.1016/j.urology.2021.12.018
Abstract: OBJECTIVE To evaluate the additional effects of mirabegron to alpha-1 adrenergic antagonist on lower urinary tract symptoms of patients who underwent 125I-brachytherapy for prostate cancer. METHODS Patients who underwent 125I-brachytherapy for prostate cancer (cT1-cT3aN0M0) in a… read more here.
Keywords: months 125i; brachytherapy; prostate cancer; 125i brachytherapy ... See more keywords
CT-guided 125I brachytherapy for recurrent ovarian cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.15905
Abstract: This retrospective study was to evaluate the local control and survival of 125I brachytherapy for recurrent ovarian cancer. 52 125I brachytherapy procedures were performed in 47 patients with 51 recurrent ovarian cancer lesions. The follow-up… read more here.
Keywords: 125i brachytherapy; ovarian cancer; recurrent ovarian;
125I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy: a comparison with best supportive care
Sign Up to like & getrecommendations! Published in 2017 at "OncoTargets and therapy"
DOI: 10.2147/ott.s129903
Abstract: Objectives The objective of this study was to assess the efficacy of computed tomography (CT)-guided 125I brachytherapy alone in improving the survival and quality of life of patients with unresectable locally advanced non-small-cell lung cancer… read more here.
Keywords: cycle first; one cycle; group; 125i brachytherapy ... See more keywords
CalliSpheres® microsphere transarterial chemoembolization combined with 125I brachytherapy for patients with non–small‐cell lung cancer liver metastases
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.882061
Abstract: Objective Poor prognosis and limited treatments of liver metastases from non–small‐cell lung cancer (NSCLC) after radical surgery are critical issues. The current study aimed to evaluate the efficacy and safety of CalliSpheres® microsphere transarterial chemoembolization… read more here.
Keywords: non small; rate; 125i brachytherapy; liver metastases ... See more keywords
Clinical efficacy of combined 125I brachytherapy and intermittent androgen deprivation for locally mediate-high risk prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "International Urology and Nephrology"
DOI: 10.3760/cma.j.issn.1673-4416.2018.01.006
Abstract: Objective To evaluate the clinical efficacy of combined 125I brachytherapy and intermittent androgen deprivation for locally mediate-high risk prostate cancer. Methods A total of 25 patients with prostate cancer ranging from 64 to 85 years… read more here.
Keywords: prostate; 125i brachytherapy; prostate cancer; androgen ... See more keywords
Efficacy and safety of computed tomography-guided 125I brachytherapy for lymph node metastatic from hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/jcrt.jcrt_245_17
Abstract: Purpose: A survival benefit may be associated with the positive control of extrahepatic lymph node metastasis (LNM) of hepatocellular carcinoma (HCC). However, no standard treatment exists. The aim of this study was to evaluate the… read more here.
Keywords: hepatocellular carcinoma; computed tomography; treatment; safety ... See more keywords
125I brachytherapy seeds implantation for an inoperable large retroperitoneal leiomyosarcoma
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/jcrt.jcrt_66_18
Abstract: Retroperitoneal leiomyosarcoma is relatively uncommon. Leiomyosarcoma has accounted for about 5%-10% of soft-tissue sarcoma, and 1/2–2/3 of the primary lesions were retroperitoneal, with a cumulative 5-year survival rate of only 35%.Leiomyosarcoma is one kind of… read more here.
Keywords: retroperitoneal leiomyosarcoma; retroperitoneal; treatment; 125i brachytherapy ... See more keywords